11 Best Performing Biotech Stocks So Far in 2025

2. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD

Year-to-Date Performance: 38.37% 

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company focused on therapies for central nervous system (CNS) disorders and rare diseases. Its key approved products include NUPLAZID for hallucinations and delusions in Parkinson’s disease psychosis, and DAYBUE for Rett syndrome, both of which have seen growing commercial traction. In Q2 2025, NUPLAZID net sales rose 7% year-over-year to $168.5 million, while DAYBUE grew 14% to $96.1 million, reaching nearly 1,000 unique patients in the U.S.

A major catalyst for 2025 is the nearing Phase 3 readout of the COMPASS trial evaluating ACP-101 in Prader-Willi Syndrome. Enrollment for this pivotal study concluded in Q2, with top-line results expected in early Q4. Positive outcomes could pave the way for a New Drug Application filing in Q1 2026 and potential approval by Q3, marking a significant expansion of the firm’s pipeline into rare neurodevelopmental disorders.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is also advancing multiple programs targeting neuropsychiatric symptoms and rare neurological diseases, including Alzheimer’s disease, psychosis, and Prader-Willi syndrome, reflecting its commitment to addressing unmet medical needs. The company highlighted these developments during its inaugural R&D Day in June 2025, unveiling nine disclosed programs, seven of which are planned to enter Phase 2 or 3 stages over 2025-2026, with five anticipated readouts through 2027.

Additionally, recent patent litigation wins secure market exclusivity for NUPLAZID through 2030, and extended formulations through 2038, providing stability for its commercial franchise. With strong product momentum, a deepening pipeline, and upcoming trial readouts, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is positioned for continued growth in CNS and rare disease therapies.